Formela Jean Francois Sells Shares of Korro Bio, Inc.
Formela Jean Francois recently sold shares of Korro Bio, Inc. for $1.70 million.
Key Points
- Formela Jean Francois sold 119,005 shares of Korro Bio, Inc. on June 23, 2026, valued at approximately $1.70 million.
- Korro Bio, Inc. has a market cap of about $200.5 million, with a 52-week range between $5.20 and $55.89.
- Analysts from firms like Citigroup and HC Wainwright & Co. have set price targets ranging from $15 to $30.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Formela Jean Francois sold 119,005 shares of Korro Bio, Inc. (NasdaqCM: KRRO) on June 23, 2026. The shares were sold at an average price of $14.25, totaling approximately $1.70 million. This transaction was part of a planned sale.
Insider Buying and Selling at Korro Bio, Inc.
In addition to the recent sale by Formela Jean Francois, other insiders have also been active. On June 24, 2026, Formela sold another 48,438 shares at an average price of $14.61. Earlier, on June 22, 2026, Formela sold 3,962 shares at $13.95. Other notable insider sales include Jeffrey Cerio, General Counsel, who sold 6,609 shares on June 16, 2026, and Oliver Dolan, Senior Vice President of Finance, who sold 3,383 shares on the same day.
Other Institutional Activity in Korro Bio, Inc.
Several institutional investors have adjusted their positions in Korro Bio, Inc. LYNX1 Capital Management LP increased its holdings by 860,381 shares, bringing its total to 1,538,296 shares valued at $17.41 million, marking a 126.9% increase. NEA Management Company, LLC added 207,100 shares, now holding 1,297,893 shares worth about $14.69 million, a 19% increase. Atlas Venture Life Science Advisors, LLC maintained its position with 1,137,149 shares valued at $12.87 million. New positions were opened by Balyasny Asset Management L.P. and Venrock Adviser, LLC, with each acquiring 1,040,054 and 1,009,500 shares, respectively.
Korro Bio, Inc. Stock Up 6.7%
Shares of Korro Bio, Inc. traded near $13.77 on Thursday. The company has a market cap of approximately $200.5 million. It operates in the biotechnology sector and has a beta of 2.096, indicating higher volatility compared to the market. The stock's 52-week low is $5.20, while its high reached $55.89. The 50-day moving average is $12.20, and the 200-day moving average is $17.71. Korro Bio has a strong liquidity position with a current ratio of 8.13 and a quick ratio of 7.71.
$KRRO stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Korro Bio reported revenue of $3.84 million with no net margin, reflecting its focus on growth and development. The company posted a negative return on equity of -87.78%, indicating ongoing investments in its pipeline. The next earnings report is expected on August 11, 2026.
Analysts Set New Price Targets
Analysts have been active in setting new price targets for Korro Bio. On May 19, 2026, HC Wainwright & Co. maintained a 'buy' rating with a $15 target. Citigroup initiated coverage on May 18, 2026, with a 'buy' rating and a $21 price target. The consensus among analysts is a 'buy' recommendation, with an average target price of $20 based on 10 opinions.
About Korro Bio, Inc.
Korro Bio, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing genetic medicines through RNA editing technology to treat rare and common diseases. The company's lead candidate, KRRO-121, targets hyperammonemia. It also collaborates with Novo Nordisk A/S on cardiometabolic diseases. Founded in 2018, Korro Bio employs 49 people under the leadership of CEO Dr. Ram Aiyar.
Bottom Line
The insider sales by Formela Jean Francois at Korro Bio, Inc. are part of planned transactions and reflect ongoing activity in the company's stock. Investors track these moves as part of broader market interest in the biotechnology sector. Remember, insider trades are disclosed after they occur and may not indicate future stock performance.
Get Korro Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KRRO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.